NCT00003095

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer

Study Contact:

Study Phase:

Recruitment Status:

COMPLETED

NCT ID:

NCT00003095

Principal Investigator:

Study Type:

OBSERVATIONAL

Official Title:

S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623

Summary

RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers.

PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine axillary lymph nodes.

Eligibility

DISEASE CHARACTERISTICS: Must be enrolled in SWOG-9623 at time of registration to this study, but must not have started treatment Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: Adult Sex: Female Menopausal status: Not specified Performance status: See Disease Characteristics Life expectancy: SWOG 0 or 1 Hematopoietic: See Disease Characteristics Hepatic: See Disease Characteristics Renal: See Disease Characteristics

PRIOR CONCURRENT THERAPY: See Disease Characteristics

Disease(s) and\or Condition(s)

Breast Cancer

Primary Purpose

Intervention/Treatment

Sponsor

SWOG Cancer Research Network